Product Updates for October 2025

RX Product

Semaglutide (Wegovy)

From: Novo Nordisk A/S

The FDA has approved a 2.4-mg injection of semaglutide for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, marking the first and only glucagon-like peptide-1 receptor agonist available for this population. The approval was based on the phase 3 ESSENCE trial (NCT04822181), in which 63% of patients on semaglutide achieved MASH resolution without fibrosis worsening compared with 34% on placebo. The trial also found semaglutide improved fibrosis outcomes and maintained efficacy across the majority of participants. The decision marks a pivotal step forward for patients with MASH, offering the first effective pharmacologic treatment for a condition that has long gone underrecognized and untreated.

For more information: novonordisk.com

Bumetanide Nasal Spray (Enbumyst)

From: Corstasis Therapeutics Inc

Bumetanide nasal spray recently received FDA approval as an outpatient diuretic therapy indicated for the treatment of adults with edema associated with congestive heart failure, liver disease, and kidney disease, including nephrotic syndrome. The approval provides a novel alternative to loop diuretics or intravenous therapy, which can have limitations blunting their effectiveness. The spray can be self-administered in an outpatient setting, which allows for more effective administration and a more tolerable experience for patients. Given the extensive expected reach of the spray, pharmacists will play a major role in ensuring access for patients and counseling them on proper use of the product.

For more information: corstasis.com

OTC Product

Magnesium+ Drink Powder

From: Ritual

Magnesium+ is a powdered supplement that mixes with water and is intended to promote relaxation, support restful sleep, and aid in muscle recovery. The product features magnesium bisglycinate, a highly absorbable form of magnesium, combined with Montmorency tart cherry, which contains polyphenols and naturally occurring melatonin and has been studied for its potential to improve sleep and reduce fatigue. The formulation is designed with attention to ingredient transparency and digestive comfort. Available in a berry flavor, Magnesium+ reflects growing demand for functional beverages in convenient, ready-to-use formats.

For more information: ritual.com

Generic Product

Iron Sucrose Injection

From: Viatris Inc

Compare to: Venofer

Viatris has received FDA approval for the first generic version of iron sucrose injection, USP, indicated for the treatment of iron deficiency anemia in adult and pediatric patients 2 years and older with chronic kidney disease. The generic, available in 50-mg/2.5-mL, 100-mg/5-mL, and 200-mg/10-mL single-dose vials, provides a lower-cost alternative to Venofer and was granted competitive generic therapy designation for select strengths, offering 180 days of market exclusivity. Safety considerations include the potential for hypersensitivity reactions, hypotension, and iron overload, requiring careful monitoring during and after administration.

For more information: viatris.com